GI
ARNA

Gradient Investments’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Gradient Investments’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3
Closed – – 680
2013
Q3 		$0 Hold
3
– – ﹤0.01% 605
2013
Q2 		$0 Buy
+3
New +$245 ﹤0.01% 500

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Gradient Investments's ARNA Position: Q4 2013 in Review

Gradient Investments sold out of Arena Pharmaceuticals Inc (ARNA) in Q4 2013, closing a stake of 3 shares.

Gradient Investments first reported a position in ARNA in Q2 2013 and held it in 2 quarters. The position peaked at $0 in Q3 2013. 134 funds tracked by Wall St. Rank hold ARNA as of Q4 2013.

  • Gradient Investments reported no remaining Arena Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Gradient Investments sold 3 Arena Pharmaceuticals Inc shares in Q4 2013.
  • Gradient Investments first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • Gradient Investments's Arena Pharmaceuticals Inc position peaked at $0 in Q3 2013.
  • 134 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q4 2013.

Based on Gradient Investments's 13F filing for Q4 2013, filed 13 Jan 2014.